Compulsory licenses in the pharmaceutical industry: pricing and R\&D strategies

DOI10.1016/J.EJOR.2019.10.021MaRDI QIDQ2286895zbMATH OpenOpenAlexFDO

Authors Archita Sarmah, Domenico De Giovanni, Pietro De Giovanni

Publication date 23 January 2020

Published in European Journal of Operational Research (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1016/j.ejor.2019.10.021

zbMATH Keywords

compulsory licensegame theorypharmaceutical industrypricingR\&D

Mathematics Subject Classification ID

Transportation, logistics and supply chain management (90B06) Applications of game theory (91A80) Production theory, theory of the firm (91B38)

Recommendations

• Compulsory licensing of pharmaceuticals by the developing South
• Therapeutic reference pricing and drug innovation incentives
• Drastic innovations and multiplicity of optimal licensing policies
• Licensing strategies in a differentiated Cournot oligopoly
• Licensing cost‐reducing innovations under supply function competition
• Optimal licensing of cost-reducing innovation
• On licensing policies in Bertrand competition
• Evaluating pharmaceutical R\&D under technical and economic uncertainty
• Reference pricing with elastic demand for pharmaceuticals

Cites work

• Don't forget your supplier when remanufacturing
• Firms' R\&D decisions under incomplete information
• Licensing radical product innovations to speed up the diffusion
• Optimal return and rebate mechanism in a closed-loop supply chain game
• Pay-as-you-throw versus recycling fund system in closed-loop supply chains with alliance recycling
• Supply chain coordination with revenue-sharing contracts: strengths and limitations

Cited in

(5)

• Compulsory licensing of pharmaceuticals by the developing South
• The value of entrant manufacturers: a study of competition and risk for donor-funded procurement of essential medicines
• Compulsory license threats in a signaling game of drug procurement
• Product line extensions and distribution channels in pharmaceutical supply chain
• Strategic analysis of drugs market pathway: regular-approval or accelerated-approval

This page was built for publication: Compulsory licenses in the pharmaceutical industry: pricing and R\&D strategies

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2286895)